Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Topic/Program Collections
    • Blog
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Topic/Program Collections
    • Blog
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
Brief Reports

A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment

Scarlett Carmen Johnson, Daniel Clay Williams, Daniel Brinton, Marshall Chew, Annie Simpson and Annie Lintzenich Andrews
Hospital Pediatrics January 2021, 11 (1) 88-93; DOI: https://doi.org/10.1542/hpeds.2020-0188
Scarlett Carmen Johnson
aDepartment of Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Clay Williams
aDepartment of Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Brinton
bCollege of Health Professions, Medical University of South Carolina, Charleston, South Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marshall Chew
bCollege of Health Professions, Medical University of South Carolina, Charleston, South Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie Simpson
bCollege of Health Professions, Medical University of South Carolina, Charleston, South Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie Lintzenich Andrews
aDepartment of Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

Article Information

vol. 11 no. 1 88-93
DOI 
https://doi.org/10.1542/hpeds.2020-0188
PubMed 
33293266

Published By 
American Academy of Pediatrics
Print ISSN 
2154-1663
Online ISSN 
2154-1671
History 
  • Published online January 1, 2021.

Article Versions

  • previous version (December 8, 2020 - 00:05).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2021 by the American Academy of Pediatrics

Author Information

  1. Scarlett Carmen Johnson, MDa,
  2. Daniel Clay Williams, MD, MSCRa,
  3. Daniel Brinton, PhDb,
  4. Marshall Chew, MSHIb,
  5. Annie Simpson, PhDb and
  6. Annie Lintzenich Andrews, MD, MSCRa
  1. aDepartment of Pediatrics and
  2. bCollege of Health Professions, Medical University of South Carolina, Charleston, South Carolina
  1. Address correspondence to Scarlett Carmen Johnson, MD, Division of General Pediatrics, Medical University of South Carolina, 135 Rutledge Ave, MSC 561, Charleston, SC 29425. E-mail: johnssca{at}musc.edu
  1. Dr Brinton participated in study design, acquisition of data and model inputs, data analysis, and critical revision of the article; Mr Chew participated in MarketScan data analysis, acquisition of data, and revising the article for important intellectual content; Dr Andrews participated in study design and concept, sensitivity analyses, and critical review and revision of the manuscript; Dr Johnson participated in study design and concept, drafting the initial manuscript, data acquisition, sensitivity analyses, and revision of the manuscript; Dr Williams participated in study design and concept and critical revision of the manuscript for important intellectual content; Dr Simpson participated in study design and concept, data analysis and interpretation, and critical revision of the manuscript for important intellectual content; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

View Full Text

Article usage

Article usage: December 2020 to December 2020

AbstractFullPdf
Dec 2020362278
PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Hospital Pediatrics: 11 (1)
Hospital Pediatrics
Vol. 11, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment
Scarlett Carmen Johnson, Daniel Clay Williams, Daniel Brinton, Marshall Chew, Annie Simpson, Annie Lintzenich Andrews
Hospital Pediatrics Jan 2021, 11 (1) 88-93; DOI: 10.1542/hpeds.2020-0188

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment
Scarlett Carmen Johnson, Daniel Clay Williams, Daniel Brinton, Marshall Chew, Annie Simpson, Annie Lintzenich Andrews
Hospital Pediatrics Jan 2021, 11 (1) 88-93; DOI: 10.1542/hpeds.2020-0188
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Characteristics of Afebrile Infants ≤60 Days of Age With Invasive Bacterial Infections
  • Trends in Incidence of Nicotine Use Disorder Among Adolescents in the Pediatric Hospital, 2012–2019
Show more Brief Reports

Similar Articles

Subjects

  • Pharmacology
    • Therapeutics
    • Pharmacology
  • Hospital Medicine
    • Hospital Medicine
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Reviewer Guidelines
  • Submit My Manuscript
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Subscribe
  • Contact Us
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • RSS Feeds
  • shopAAP
  • AAP.org
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
American Academy of Pediatrics

© 2021 American Academy of Pediatrics